The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | Treating CLL with venetoclax
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discusses using venetoclax in the treatment of patients with chronic lymphocytic leukemia (CLL). Venetoclax will be approved for high risk CLL patients with 17p deletions, and has received good results in studies. Furthermore it has performed well in contrast with ibrutinib or idelalisib, as complete responses (CR) and minimal residual disease (MRD) negativity in relapsed/refractory CLL has been reported – even in monotherapy. Dr Eichhorst also discusses combinations with the CD20 antibody. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
